Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Travere Therapeutics
Biotech
Midsize biotechs form coalition to fight against MFN policy
A group of 10 domestic, medium-sized biotechs launched the Midsized Biotech Alliance of America to advocate for free-market solutions to drug policy.
Will Maddox
Feb 25, 2026 1:05pm
Amicus pays Dimerix $30M for late-phase rare kidney disease drug
May 1, 2025 10:59am
Travere fails to beat off-label blood pressure drug in phase 3
May 2, 2023 7:00am
FDA’s liver safety request set to delay decision on Travere drug
Oct 14, 2022 10:05am
Vifor doles out $55M upfront to license Travere's asset
Sep 16, 2021 11:41am
FDA sets back Travere's plans for kidney disease drug approval
May 26, 2021 8:10am
